267 related articles for article (PubMed ID: 15930295)
21. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
[TBL] [Abstract][Full Text] [Related]
22. 1alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway.
Murthy S; Weigel NL
Prostate; 2004 May; 59(3):282-91. PubMed ID: 15042604
[TBL] [Abstract][Full Text] [Related]
23. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
24. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
[TBL] [Abstract][Full Text] [Related]
25. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Yu S; Wang X; Ng CF; Chen S; Chan FL
Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a vitamin D3-resistant MCF-7 cell line.
Narvaez CJ; Vanweelden K; Byrne I; Welsh J
Endocrinology; 1996 Feb; 137(2):400-9. PubMed ID: 8593782
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
Campbell MJ; Reddy GS; Koeffler HP
J Cell Biochem; 1997 Sep; 66(3):413-25. PubMed ID: 9257197
[TBL] [Abstract][Full Text] [Related]
29. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
[TBL] [Abstract][Full Text] [Related]
30. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1993 May; 132(5):1952-60. PubMed ID: 7682937
[TBL] [Abstract][Full Text] [Related]
31. Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells.
Koga M; Eisman JA; Sutherland RL
Cancer Res; 1988 May; 48(10):2734-9. PubMed ID: 2834048
[TBL] [Abstract][Full Text] [Related]
32. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3.
Miller GJ; Stapleton GE; Ferrara JA; Lucia MS; Pfister S; Hedlund TE; Upadhya P
Cancer Res; 1992 Feb; 52(3):515-20. PubMed ID: 1370648
[TBL] [Abstract][Full Text] [Related]
33. Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.
Yano S; Matsuyama H; Hirata H; Inoue R; Matsumoto H; Ohmi C; Miura K; Shirai M; Iizuka N; Naito K
Oncol Rep; 2006 Jun; 15(6):1453-60. PubMed ID: 16685379
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells.
Golovko O; Nazarova N; Tuohimaa P
Life Sci; 2005 Jun; 77(5):562-77. PubMed ID: 15904673
[TBL] [Abstract][Full Text] [Related]
35. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D.
Flanagan JN; Young MV; Persons KS; Wang L; Mathieu JS; Whitlatch LW; Holick MF; Chen TC
Anticancer Res; 2006; 26(4A):2567-72. PubMed ID: 16886665
[TBL] [Abstract][Full Text] [Related]
37. 1,25(OH)
Abu El Maaty MA; Alborzinia H; Khan SJ; Büttner M; Wölfl S
Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1618-1630. PubMed ID: 28651973
[TBL] [Abstract][Full Text] [Related]
38. Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells.
Bratland A; Risberg K; Maelandsmo GM; Gützkow KB; Olsen OE; Moghaddam A; Wang MY; Hansen CM; Blomhoff HK; Berg JP; Fodstad O; Ree AH
Cancer Res; 2000 Oct; 60(19):5578-83. PubMed ID: 11034106
[TBL] [Abstract][Full Text] [Related]
39. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
Barreto AM; Schwartz GG; Woodruff R; Cramer SD
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
[TBL] [Abstract][Full Text] [Related]
40. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3.
Schwartz GG; Whitlatch LW; Chen TC; Lokeshwar BL; Holick MF
Cancer Epidemiol Biomarkers Prev; 1998 May; 7(5):391-5. PubMed ID: 9610788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
